Review
Published on 24 Apr 2023
Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations
in Cancer Cell Biology
Frontiers in Cell and Developmental Biology
doi 10.3389/fcell.2023.1170444
- 2,907 views
- 3 citations

